CHA Vaccine Institute

2:45 PM - 3:00 PM (EDT), Monday, June 5, 2023 ・ Session Room 104C
CHA Vaccine Institute (CVI) is a clinical stage biopharmaceutical company developing proprietary Toll-like receptor (TLR) ligand based adjuvant systems and vaccines for infectious disease and cancer.
CVI's adjuvants consist of a TLR 2 ligand and a TLR 3 ligand which synergistically enhance humoral and cellular immunity. They show an excellent immune boosting efficacy over conventional vaccine adjuvants and superior tolerability as well.
And CVI's adjuvants are provided in various formulations in order to deliver various kinds of antigens, make the vaccine formulation easy, and effectively elicit immune responses for each indication.
CVI's adjuvants are clinically proven over 200 patients and their application ranges from hepatitis B, Herpes Zoster, Influenza, COVID-19, Norovirus to cancer vaccines and immuno-oncology.
CVI is actively seeking partners that share its vision of developing vaccines and therapies which will reduce death and suffering from diseases.
Company Type:
Publicly Traded Company
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
Main Therapeutic Focus:
Multiple Therapeutics
Lead Product in Development:
CVI-HBV-002 (Therapeutic vaccine for chronic hepatitis B)
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
CHA Vaccine Institute